2025 Poster Presentations

Best of Show Poster Awards will be announced Wednesday during the 10:00am Coffee Break and Thursday during the 1:35pm Dessert Break

POSTER SESSION A (Tuesday-Wednesday morning)

A01: From Genetic Insight to Phase 2b in Under 2 years: The 5Prime × Marea Story, Presented by Brent R., 5 Prime Sciences, Inc.

A02: A Continuous Enzymatic Assay Identifies and Characterizes Kinetic Modes of Action to Drive Drug Discovery, Presented by Earl M., AssayQuant Technologies, Inc.

A03: Bridging Biochemistry and Biology: Continuous Kinase Activity Assays with Complex Samples, Presented by Erik S., AssayQuant Technologies, Inc.

A04: Leveraging Virus-Like Particle (VLP) Technology for Antibody Discovery Against Complex Membrane Protein Targets Through In Vitro Display, Presented by Crystal C., AstraZeneca

A05: Higher Throughput Proteomics Screens for Degrader Selectivity Profiling, Presented by Anthony I., AstraZeneca

A06: AbDrop™ Speeds: Accelerating Your Antibody Discovery with Single B Solution, Presented by Haoming Z., Biointron

A07: Characterizing Binding Affinity and Avidity of Anti-HER1, Anti-HER2 and Anti-HER3 Therapeutic Antibodies in Whole Single Cells Using Label-Free Surface Plasmon Resonance Microscopy (SPRM), Presented by Jesus A., Biosensing Instrument

A08: From GLP-1 to Amylin: Development of Reporter Cell Lines for Next-Generation Metabolic Therapeutics, Presented by Veronique B., BPS Bioscience, Inc.

A09: Development of ATPase and Helicase Assays for DHX9, BLM, and WRN-Targeted Drug Discovery, Presented by Pavel S., BPS Bioscience, Inc.

A10: Implementation of Synthetic Antibody Libraries for Biotherapeutic Discovery, Presented by Rose D., Bristol Myers Squibb

A11: Molecular Glue/PROTAC Target ID Using HuProt Human Proteome Arrays, Presented by Eric J., CDI Labs, Inc.

A12: A Novel In Vitro Platform for Evaluating Molecular Glue Degraders: Targeting VAV1 to Modulate Immune Signaling, Presented by Carlo P., ChemPartner

A13: Advancing Drug Discovery Through Cytokine–Cytokine Receptor Interaction Platform, Presented by Yuzhou X., ChemPartner

A14: Degraders on Target: Evaluating the Potential of this Novel Drug Class, Presented by Kinsi O., Clarivate

A15: Concept’s Direct to Biology (D2B) Approach to PROTAC Drug Discovery - A Streamlined Workflow for Innovative Fast Tracking of PROTACs, Presented by Ralph K., Concept Life Sciences

A16: GPCR PAR1 or DRD2-Specific Monoclonal Antibodies Can Detect the Target Expressed on Live Cell Surfaces by Flow Cytometry, Presented by Shixia W., Conigen Bioscience

A17: iCLASS: Live-Cell Ligand Discovery Platform for “Hard-to-Drug” Protein Targets, Presented by Taleb S., Dalriada Drug Discovery, Inc.

A18: Enabling Hit Discovery with DEL-Pilot, Off-the-Shelf Libraries, Custom Synthesis, and Bespoke Library Pools, Presented by Svetlana B., DEL Source

A19: Accelerating Covalent Drug Discovery with AI and Warhead Diversity for Challenging Targets, Presented by Ghotas E., DEL Source

A20: Molecular Matchmakers: Finding the Perfect Glue, Presented by Chris M., Domainex Ltd.

A21: Accelerated Covalent Fragment Hit Discovery for KRAS [G12C] Using Mass Spectrometry and Direct-to-Biology Screening, Presented by Andrew R., Domainex Ltd.

A22: HM100789, a Novel MAT2A Inhibitor, Demonstrates Antitumor Efficacy Through Synthetic Lethality in MTAP-Deficient Tumors, Presented by Miyoung L., Hanmi Pharmaceutical Co Ltd

A23: Development and Application of an Integrated GPCR-Centric Screening Platform for Anti-Obesity Drug Discovery, Presented by Tiejun B., ICE Bioscience

A24: Building a TPD Discovery Platform for Autoimmune Therapeutics: From Biophysical Screening to In Vivo Validation, Presented by Cong H., ICE Bioscience

A25: ML-Driven Drug Discovery with DNA-Encoded Libraries, Presented by Virja A., Insitro, Inc.

A26: Epitope Specific Antibody Discovery Against the μ Opioid Receptor, Presented by Nirakar B., Institute for Protein Innovation

A27: Advanced Quantum Methods for Next-Gen Drug Design: Unlocking Challenging Enzymes and Covalent Reactivity, Presented by Vid S., Kuano Ltd.

A28: K-RAS Molecular Glue Degrader: Coopting Novel Ligases for Discovery of Molecular Glues, Presented by Muhammad A., LifeSensors, Inc.

A29: HTS Screening of Poly-Ubiquitin Linkage-Specific Molecular Glues and Protein Degraders, Presented by Kamau F., LifeSensors, Inc.

A30: A Graph Knowledge Base for Multi-Omics Entity Mapping and Integration: Bridging Experimental and External Knowledge Layers, Presented by Andrew W., Mass Dynamics

A31: A CRISPR-Based Platform for Characterizing and Rescuing mRNA Splicing Mutations, Presented by Paolo P., Massachusetts General Hospital

A32: An Analytical Platform for Rational Design of Nucleic Acid Therapeutics for Intracellular Delivery, Presented by Martin M., Medicines Discovery Catapult

A33: A Novel Approach to Target Engagement for Drug Discovery, Presented by Paul O., Selvita / Medicines Discovery Catapult

A34: Harnessing Ionizing Radiation for Spatiotemporal Control of Induced Covalent Chemistry, Presented by Oluwatosin A., National Institutes of Health, National Cancer Institute

A35: Biochemical Proximity-Based Assay Profiling to Evaluate Cross-Platform Reproducibility in Identifying High-Throughput Screening Hits, Presented by Tanishka S., National Institutes of Health, National Center for Advancing Translational Sciences

A36: Functional Membrane Proteins - Ready in 48 Hours, Presented by Aujan M., Nuclera

A37: Discovery and Characterisation of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo Active KAT6AB Inhibitor, Presented by Daniel K., Nuvisan ICB GmbH

A38: ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds, Presented by Catherine S., o2h Ltd.

A39: OGAP®-Diabetes: Proteomics-Based Target Discovery Platform for Type 2 Diabetes Mellitus, Presented by Joe L., Oxford Biotherapeutics

A40: High-Throughput and Cost-Effective Transcriptomics for Interrogating Compound and CRISPR Perturbations in Cells, Presented by Shijie Z., Pfizer, Inc.

A41: Accelerating Discovery by Unlocking Novel Live Cell Assays with a Silicon Membrane-Based Platform for Mechanical Delivery of Impermeable Bi-Functionals, Peptides, and Probes, Presented by Crystal T., Portal Biotechnologies

A42: Live Cell NanoBRET®-TE Assays for WRN and Synthetic Lethal Targets in the DNA Damage Response Pathway, Presented by Kristin H., Promega Corporation

A43: Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors, Presented by Andrew Z., Promega Corporation

A44: High-Throughput Antibody Engineering via Deep Mutational Scanning and Single-Molecule Fluorescence Imaging for Affinity and Developability Optimization, Presented by John J., PROTEINA

A45: Deep Learning Detects Evolutionary Patterns in the Natural Product Space, Presented by Anton S., Purdue University

A46: Apparent Potency of Small Molecule Inhibitors is Influenced By the Choice of Substrate in LIMK Biochemical In-Vitro Kinase Activity Assays, Presented by Josh B., Reaction Biology

A47: Cell-Free Preparation of Human Membrane Proteins for Structural Biology and Drug Development, Presented by Shigeyuki Y., Shinshu University

A48: Hide and Seek: Assessing Druggability and Uncovering Cryptic Pockets, Presented by Mussa Q., Sygnature Discovery

A49: A Data-Driven Systemic Framework for Drug Target Prioritization, Presented by Achintya D., Syngene International Ltd.

A50: Harnessing Sphingolipid Biology for the Targeted Extracellular Protein Degradation, Presented by Justin W., Transcera

A51: Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays, Presented by Ishrat J., WuXi AppTec

A52: In Vitro Proximity and Ubiquitylation Assays for CRBN, VHL and Emerging Ligases of Interest in TPD, Presented by Bradley B., Trilogie Bioscience

A53: Molecular Dynamics Simulations of Metabolite and Peptide Fibrils, Presented by Pavel R., University of Illinois Chicago

A54: Hit Optimization Studies in a Series of 2,5-Substituted Pyrimidine Inhibitors of Slack Potassium Channels, Presented by Yasmeen M., University of North Texas

A55: Selective Enhancement of Glycolysis Using a Covalent PFKL Activator, Presented by Xiaoding J., University of Texas at Austin

A56: Discovery of Irreversible Ligands Targeting Functional Tyrosine and Lysine in Living Cells via Activated Sulfonate Esters, Presented by Gibae K., University of Texas at Austin

A57: Antibody Discovery for Complex Membrane Antigens, Presented by Ernest S., Vaccinex, Inc.

A58: Recent Trends, Limitations, and New Opportunities in Covalent Drug Discovery, Presented by Jeffrey S., X-Chem

POSTER SESSION B (Wednesday afternoon-Thursday)

B01: Discovery of GPCR Agonist Antibodies with Unique Activation Mechanisms Using the FAST Platform, Presented by Monica S., Abalone Bio

B02: Strategies for Tailoring T-Cell Engager Design for Solid Tumor Indications, Presented by Marta S., AbCellera

B03: Engineering a Panel of Potent and Developable Anti-CD3 Antibodies for Conditional Activation in the Tumor Microenvironment, Presented by Daniel W., Adimab LLC

B04: Safer pHLA-Targeted Immunotherapies Through AI and Computational Immunology, Presented by Maciej J., Ardigen

B05: Precision Screening for Neurodegeneration: HiBiT Assay and Gene Expression in Action, Presented by Daniele C., Axxam

B06: Differential Scanning Fluorimetry Screening and Biophysical Assays Identify Novel Small Molecule Binders of Pre-miR-21, Presented by Tom G., Axxam

B07: Speed Counts While Quality Matters: A Fast-Track Approach to Bispecific Antibody Production, Presented by Huanyi Y., Biointron

B08: Selectivity and Cooperativity of PROTAC®s Using HT-SPR, Presented by Nicholas A., Carterra

B09: Massively Parallel SPR-Based Fragment Screening of Kinase Arrays, Presented by Christian G., Carterra

B10: Fragment-Based Drug Discovery (FBDD) Approach for IRAK4, Presented by Zahra A., Cayman Chemical Company

B11: Develop the Toolbox for Targeted Protein Degradation (TPD)-Based Drug Discovery, Presented by Hu L., ChemPartner

B12: The UFL Fragment Library Design Platform and an In-Silico Platform for Rapid Fragment Optimization, Presented by Laszlo K., ChemPass Ltd.

B13: Rapid and Highly Cost-Effective Giga-Scale Virtual Screening, Presented by Greg M., ChemPass Ltd.

B14: Approaches to Efficient Exploration of Large Combinatorial Spaces, Presented by Anna K., Chemspace

B15: Generation of Custom Synthetically Accessible Combinatorial Chemical Spaces Using Machine Learning-Based Reagent Filtering – Design of Freedom Space 4.0, Presented by Mariia T., Chemspace

B16: Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI, Presented by Steven H., Concept Life Sciences

B17: Recombinant Bioactive CXCR4 or CXCR5 on Virus-Like Nanoparticles Can Bind to Their Chemokine Ligand CXCL12 or CXCL13, Presented by Jean Q., Conigen Bioscience

B18: A New Era for Full-Length Membrane Targets: From Lysate to Structure- and Assay-Ready Protein in 45 Minutes, Presented by Barbara M., Cube Biotech GmbH

B19: Using Direct-to-Biology in a Spectral Shift-PoLiPa Platform to Enable Fast Fragment Follow-Up for A2a Antagonists, Presented by Ray B., Domainex Ltd.

B20: Data Challenges and Innovations in ASMS Screening, Presented by Didier R., Edelris SAS

B21: Engineering CRBN and Applying REAL Technology for Rapid Identification of Next Generation CRBN Binders: Design and Activity Evaluation of New Molecular Glue Library and CRBN Ligand-Linker Conjugates, Presented by Dave H., Enamine Ltd.

B22: Integrated Solutions for STAT Inhibition and Targeted Protein Degradation: Enabling Novel Therapies for Cancer, Inflammation and Autoimmune Disease, Presented by Jean B., Eurofins Discovery

B23: Characterization of Molecular Glues, Presented by Travis M., Fida Biosystems

B24: Structural and Functional Basis of PU.1-BAF Interaction Reveals a Novel Interface for Targeting Undruggable Transcription Factors, Presented by Jozlyn C., Foghorn Therapeutics

B25: Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates, Presented by Jacob S., Genovac

B26: Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seq, Presented by Lauren B., Ginkgo Bioworks

B27: Automated High-Throughput ADME Assays for AI/ML in Drug Discovery, Presented by Nina W., Ginkgo Bioworks

B28: Ligand-Based CRBN Molecular Glue Library: Design, Screening, and Application in Hit Discovery, Presented by Zhenyu W., HitChem

B29: A Novel Screening and Machine Learning Method for Cytochrome P450 Induction in Early Drug Discovery Using Advanced Biomimetic Chromatography Targeting the Pregnane X Receptor, Presented by Hiroko O., Japan Tobacco, Inc.

B30: Accelerating Drug Discovery with Scalable Electroporation and Assay Ready Cells, Presented by James B., MaxCyte, Inc.

B31: A Computational Chemistry and AI-Driven Framework for Structure-Based Drug Design Informed by Underlying Factors of Mutation-Induced Drug Resistance: A Study of KRAS, Presented by Katarzyna M., Moffitt Cancer Center & Research Institute

B32: Profiling the Molport In-Stock Compound Database Based on Emerging Drug Discovery Trends, Presented by Diana ZG., Molport

B33: NanoSyrinx Platform for Targeted Payload Delivery, Presented by Valentina G., NanoSyrinx Ltd.

B34: Bivalency Enables the Design of High Affinity and Specificity Ligands for the MYCN G-Quadruplex, Presented by Mo Y., National Institutes of Health, National Cancer Institute

B35: Identification of a Submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the Synergy of DEL and PROTAC Technologies, Presented by Viviane B., Novalix

B36: Overcoming the Challenge of Producing Highly Disordered Transcription Factors with eProtein Discovery™, Presented by Ruben T., Nuclera

B37: Innovative Bioluminescence Assays for Monitoring GPCR Dynamics: Advancing Therapeutic Strategies for Metabolic Disease, Presented by Megan L., Promega Corporation

B38: Assessment of a Bi-Specific Macrophage Engager (BiME) in a Co-Injection Tumor Model for Ovarian Cancer, Presented by Kelsey R., QIMA Life Sciences

B39: Quantum Prediction of KRAS G12C Drug Binding Affinities via Fragment Molecular Orbital (FMO) Method, Presented by Jaehong S., Qunova Computing, Inc.

B40: In Vitro Comparison of Kadcyla® and Enhertu® in Breast Cancer with Varying HER2 Expression: Proliferation, Internalization, Bystander Effects and Toxicity, Presented by Liz B., Reaction Biology

B41: Optimization of Nurr1 Agonists in Drug Development for Neurodegenerative Diseases, Presented by Ian Mitchelle D., Saint Louis University

B42: The Lonesome Orphan is Fostered: GCNF Synthetic Modulators Identified, Presented by Don M., Saint Louis University

B43: Discovery of Novel Therapeutics Against GPCRs, Ion Channels and Transporters with the Salipro® Platform, Presented by Peter J., Salipro Biotech AB

B44: Structural Insights into Targeting IL-23 with Different Modalities, Presented by Kenth H., SARomics Biostructures AB

B45: Seeking New Glues: Toward a Ligase-Agnostic Platform for Molecular Glue Degrader Discovery, Presented by Helen B., Sygnature Discovery

B46: Design of Allosteric Modulators that Change GPCR G Protein Subtype Selectivity, Presented by Lauren S., University of Minnesota

B47: Discovery of Novel Dual EGFR/FGFR1 Inhibitors via AI-Driven Design and Synthesis, Presented by Peter G., Variational AI

B48: DELs in Cells – Integral Membrane Screening, Presented by Leif K., Vipergen ApS

B49: Radiometabolic Analysis for Sphingosine-1-Phosphate Receptor 1 (S1PR1) Specific PET-Radiotracers In Vivo, Presented by Lin Q., Washington University

B50: An Integrated Platform of Microenvironment-Preserved Organoids (ALI-PDO) and Functional Genomics for Novel Oncology Target Discovery and Drug Screening, Presented by Wei H., TRiCBiO Biotech Co., Ltd.

B51: Advancing Macrocyclic DNA-Encoded Libraries for Challenging Targets, Presented by Ali C., X-Chem

B52: Exploration, Exploitation and Summarization: Leveraging Thompson Sampling, Deep Data Mining and Pharmacophore Modeling to Access the Wealth of DEL Data for Drug Design Acceleration, Presented by Rebecca S., X-Chem

B53: Discovery and Optimization of Kv7.4 Channel (KCNQ4) Selective Activator for Treatment of Hearing Loss, Presented by Sanghwa L., Yonsei University

B54: From Reactivity to Selectivity: Unlocking Covalent Screening, Presented by Johan V., ZoBio BV

ADDITIONAL VIRTUAL POSTERS

V1: Development and Characterization of GelMA Hydrogel Containing Temozolomide and YAP siRNA Loaded in Trimethyl Chitosan-Hyaluronate Nanoparticles for Localized Drug Delivery to Glioblastoma Tumors, Presented by Aryan F., Tehran University of Medical Sciences